The Role of Methyltransferase NSD2 as a Potential Oncogene in Human Solid Tumors.

Abstract

Malignant solid tumors are the leading cause of death in humans, and epigenetic regulation plays a significant role in studying the mechanism of human solid tumors. Recently, histone lysine methylation has been demonstrated to be involved in the development of human solid tumors due to its epigenetic stability and some other advantages. The 90-kb protein methyltransferase nuclear receptor SET domain-containing 2 (NSD2) is a member of nuclear receptor SET domain-containing (NSD) protein lysine methyltransferase (KMT) family, which can cause epigenomic aberrations via altering the methylation states. Studies have shown that NSD2 is frequently over-expressed in multiple types of aggressive solid tumors, including breast cancer, renal cancer, prostate cancer, cervical cancer, and osteosarcoma, and such up-regulation has been linked to poor prognosis and recurrence. Further studies have identified that over-expression of NSD2 promotes cell proliferation, migration, invasion, and epithelial-mesenchymal transformation (EMT), suggesting its potential oncogenic role in solid tumors. Moreover, Gene Expression Profiling Interactive Analysis (GEPIA) was searched for validation of prognostic value of NSD2 in human solid tumors. However, the underlying specific mechanism remains unclear. In our present work, we summarized the latest advances in NSD2 expression and clinical applications in solid tumors, and our findings provided valuable insights into the targeted therapeutic regimens of solid tumors.

• Authors: Rui Chen, Yan Chen, Weiqing Zhao, Cheng Fang, Wenjie Zhou, Xin Yang, Mei Ji
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 13 Pg. 6837-6846 ( 2020) ISSN: 1178-6930 [Print] New Zealand
• PMID: 32764971 (Publication Type: Journal Article, Review)
• Copyright: © 2020 Chen et al.